See more : NatWest Group plc (NWG.L) Income Statement Analysis – Financial Results
Complete financial analysis of China Life Insurance Company Limited (CILJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China Life Insurance Company Limited, a leading company in the Insurance – Life industry within the Financial Services sector.
You may be interested
- Lumina Group Limited (1162.HK) Income Statement Analysis – Financial Results
- Quantafuel ASA (QNTFF) Income Statement Analysis – Financial Results
- The Okinawa Electric Power Company, Incorporated (9511.T) Income Statement Analysis – Financial Results
- Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS) Income Statement Analysis – Financial Results
- Ceres Power Holdings plc (CWR.L) Income Statement Analysis – Financial Results
China Life Insurance Company Limited (CILJF)
About China Life Insurance Company Limited
China Life Insurance Company Limited, together with its subsidiaries, operates as a life insurance company in the People's Republic of China. The company operates in four segments: Life Insurance Business, Health Insurance Business, Accident Insurance Business, and Other Businesses. It offers critical illness protection, annuity, children/women/pension, security, life, medical, and accident protection insurance products. The company was founded in 1949 and is based in Beijing, the People's Republic of China. China Life Insurance Company Limited is a subsidiary of China Life Insurance (Group) Company Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 734.85B | 803.98B | 824.53B | 804.96B | 729.47B | 627.42B | 643.36B | 540.78B | 507.45B | 440.77B | 417.88B | 371.49B | 370.90B | 385.84B | 339.29B | 166.81B | 191.37B | 147.31B | 98.21B | 76.81B | 78.88B | 74.31B | 61.21B |
| Cost of Revenue | -89.21B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 824.06B | 803.98B | 824.53B | 804.96B | 729.47B | 627.42B | 643.36B | 540.78B | 507.45B | 440.77B | 417.88B | 371.49B | 370.90B | 385.84B | 339.29B | 166.81B | 191.37B | 147.31B | 98.21B | 76.81B | 78.88B | 74.31B | 61.21B |
| Gross Profit Ratio | 112.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.08B | 39.87B | 40.81B | 37.69B | 40.28B | 37.49B | 35.95B | 31.85B | 27.46B | 25.43B | 24.81B | 23.28B | 0.00 | 20.29B | 18.72B | 12.11B | 11.80B | 9.34B | 7.24B | 6.59B | 6.86B | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.89B | 2.92B | 2.67B | 3.23B | 3.08B | 3.23B | 2.83B | 2.51B | 2.47B | 2.68B | 3.01B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.08B | 39.87B | 40.81B | 37.69B | 40.28B | 37.49B | 35.95B | 31.85B | 27.46B | 25.43B | 24.81B | 23.28B | 21.55B | 20.29B | 18.72B | 12.11B | 11.80B | 9.34B | 7.24B | 6.59B | 6.86B | 0.00 | 5.10B |
| Other Expenses | 682.48B | -830.62B | -826.34B | -798.59B | -718.88B | -659.62B | -96.94B | -91.11B | -59.83B | 0.00 | 0.00 | 0.00 | -375.20B | -368.34B | -319.05B | -150.88B | -158.19B | -132.64B | -95.43B | -74.66B | -86.97B | -77.02B | -70.98B |
| Operating Expenses | 722.61B | -790.74B | -785.53B | -760.91B | -678.60B | -622.14B | 96.94B | 91.11B | 59.83B | 300.88B | 320.69B | 318.26B | -353.66B | -348.05B | -300.33B | -138.77B | -146.39B | -123.30B | -88.19B | -68.07B | -80.11B | -77.02B | -65.88B |
| Cost & Expenses | 722.61B | 779.93B | 774.03B | 750.47B | 669.68B | 613.50B | 601.68B | 516.94B | 461.52B | 400.36B | 388.43B | 360.52B | 350.39B | 344.83B | 297.55B | 144.01B | 145.98B | 121.71B | 86.70B | 67.30B | 79.15B | 1.66B | 7.28B |
| Interest Income | 0.00 | 0.00 | 0.00 | 13.03B | 15.65B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.35B | 0.00 | 2.68B | -3.97B | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.86B | 5.60B | 3.75B | 4.26B | 4.12B | 4.60B | 4.77B | 4.32B | 4.73B | 4.03B | 2.58B | 873.00M | 27.26B | 0.00 | 0.00 | 0.00 | -164.98B | 705.00M | 9.50B | 1.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 4.76B | 5.29B | 4.88B | 4.75B | 4.38B | 2.45B | 2.18B | 2.04B | 2.04B | 2.12B | 2.03B | 1.95B | 1.91B | 1.80B | 1.56B | 1.35B | 14.53B | 11.17B | 8.71B | 6.92B | 6.31B | 0.00 | 0.00 |
| EBITDA | 0.00 | 18.52B | 44.29B | 106.99B | 167.54B | 25.70B | 47.58B | 30.40B | 51.88B | 46.68B | 37.54B | 9.40B | 49.70B | 69.91B | 40.52B | 23.93B | 59.51B | 22.10B | 18.74B | 15.65B | 5.09B | -2.71B | -4.67B |
| EBITDA Ratio | 0.00% | 2.30% | 5.37% | 6.11% | 7.57% | 1.26% | 5.58% | 3.51% | 8.36% | 8.63% | 6.44% | 2.53% | 5.16% | 10.26% | 11.94% | 17.62% | 31.10% | 23.88% | 19.08% | 20.38% | 6.45% | -3.64% | -7.63% |
| Operating Income | 12.24B | 13.23B | 39.00B | 44.06B | 50.87B | 5.28B | 33.68B | 16.92B | 40.38B | 35.91B | 24.88B | 7.45B | 17.24B | 37.79B | 38.96B | 28.04B | 44.98B | 24.01B | 10.02B | 8.73B | -1.22B | -2.71B | -4.67B |
| Operating Income Ratio | 1.67% | 1.65% | 4.73% | 5.47% | 6.97% | 0.84% | 5.23% | 3.13% | 7.96% | 8.15% | 5.95% | 2.01% | 4.65% | 9.79% | 11.48% | 16.81% | 23.51% | 16.30% | 10.20% | 11.37% | -1.55% | -3.64% | -7.63% |
| Total Other Income/Expenses | -363.00M | 10.82B | 11.34B | 10.42B | -39.66B | 8.64B | 736.00M | 139.00M | 285.00M | 460.00M | 950.00M | 0.00 | 3.27B | 1.77B | 704.00M | -8.08B | 409.00M | 0.00 | 0.00 | -6.35B | 959.00M | -803.00M | 6.00M |
| Income Before Tax | 11.88B | 24.05B | 50.50B | 54.49B | 59.80B | 13.92B | 41.67B | 23.84B | 45.93B | 40.40B | 29.45B | 10.97B | 20.51B | 41.01B | 41.75B | 22.80B | 45.39B | 25.61B | 11.51B | 9.50B | -263.00M | -3.51B | -4.70B |
| Income Before Tax Ratio | 1.62% | 2.99% | 6.12% | 6.77% | 8.20% | 2.22% | 6.48% | 4.41% | 9.05% | 9.17% | 7.05% | 2.95% | 5.53% | 10.63% | 12.30% | 13.67% | 23.72% | 17.38% | 11.72% | 12.37% | -0.33% | -4.72% | -7.68% |
| Income Tax Expense | -10.76B | -9.47B | -1.92B | 3.10B | 781.00M | 1.99B | 8.92B | 4.26B | 10.74B | 7.89B | 4.44B | -304.00M | 2.02B | 7.20B | 8.71B | 1.39B | 6.33B | 5.55B | 2.15B | 2.28B | 1.18B | 14.00M | 4.00M |
| Net Income | 21.11B | 32.08B | 50.77B | 50.26B | 58.29B | 11.40B | 32.25B | 19.13B | 34.70B | 32.21B | 24.77B | 11.06B | 18.33B | 33.63B | 32.88B | 21.28B | 39.06B | 20.05B | 9.37B | 7.17B | -1.43B | -3.52B | -4.71B |
| Net Income Ratio | 2.87% | 3.99% | 6.16% | 6.24% | 7.99% | 1.82% | 5.01% | 3.54% | 6.84% | 7.31% | 5.93% | 2.98% | 4.94% | 8.72% | 9.69% | 12.76% | 20.41% | 13.61% | 9.54% | 9.34% | -1.81% | -4.74% | -7.70% |
| EPS | 0.75 | 1.14 | 1.80 | 1.78 | 2.05 | 0.40 | 1.13 | 0.66 | 1.22 | 1.14 | 0.88 | 0.39 | 0.65 | 1.19 | 1.16 | 0.68 | 1.38 | 0.75 | 0.35 | 0.10 | -0.07 | -0.18 | -0.09 |
| EPS Diluted | 0.75 | 1.14 | 1.80 | 1.78 | 2.05 | 0.40 | 1.13 | 0.66 | 1.22 | 1.14 | 0.88 | 0.39 | 0.65 | 1.19 | 1.16 | 0.68 | 1.38 | 0.75 | 0.35 | 0.10 | -0.07 | -0.18 | -0.09 |
| Weighted Avg Shares Out | 28.27B | 28.27B | 28.27B | 28.27B | 28.27B | 28.26B | 28.27B | 28.27B | 28.27B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 26.61B | 26.58B | 70.82B | 20.48B | 19.58B | 52.29B |
| Weighted Avg Shares Out (Dil) | 28.27B | 28.27B | 28.27B | 28.27B | 28.43B | 28.26B | 28.54B | 28.98B | 28.44B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 28.26B | 26.61B | 26.58B | 70.82B | 20.48B | 19.58B | 52.29B |
China Life Insurance Company Limited (CILJF) Q3 2024 Earnings Call Transcript
China Life Insurance Company Limited (OTCPK:CILJF) Q3 2024 Earnings Conference Call October 30, 2024 7:00 AM ET Company Participants Li Yinghui - Investor Relations, China Life Insurance Co Ltd Grace Hou - Head of Investor Relation Bai Kai - Vice...
China Life Insurance Company Limited (CILJF) Q2 2024 Earnings Conference Call Transcript
China Life Insurance Company Limited (OTCPK:CILJF) Q2 2024 Earnings Conference Call August 29, 2024 9:00 PM ET Company Participants Tang Xin - Culture and Brand Development, a Department General Manager Li Mingguang - President and Executive Director Liu Hui -...
China Life Insurance Company Limited (CILJF) Q4 2023 Earnings Call Transcript
China Life Insurance Company Limited (CILJF) Q4 2023 Earnings Call Transcript
China Life Insurance Company Limited Intends to Deregister and Terminate Its Reporting Obligations Under the U.S. Securities Exchange Act of 1934
BEIJING , Nov. 13, 2023 /PRNewswire/ -- China Life Insurance Company Limited (the "Company") (SSE: 601628; HKSE: 2628) announced today that the Company intends to deregister with the United States Securities and Exchange Commission (the "SEC") and terminate its reporting...
China Life Insurance Company Limited (CILJF) Q3 2023 Earnings Call Transcript
China Life Insurance Company Limited (OTCPK:CILJF) Q3 2023 Earnings Conference Call October 26, 2023 7:00 AM ET Company Participants Hu Jin - Chief Financial Officer Conference Call Participants Thomas Wong - Goldman Sachs Michelle Ma - Citi Tang Shengbo -...
CHINA LIFE INSURANCE COMPANY LIMITED ANNOUNCES 2023 INTERIM RESULTS (H SHARES)
HONG KONG , Aug. 23, 2023 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628) announces the unaudited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the six months ended 30 June...
China Life Insurance Company Limited (CILJF) Q4 2022 Earnings Call Transcript
China Life Insurance Company Limited (OTCPK:CILJF) Q4 2022 Earnings Conference Call March 29, 2023 11:00 PM ET Company Participants Zhao Guodong - Assistant President and Board Secretary Bai Tao - Chairman Li Mingguang - Vice President and Chief Actuary Ruan...
China Life Insurance: Continues To Offer Good Value
China Life's valuation is very attractive based on financial fundamentals.
HSBC Gets Nod to Buy Remaining Stake in China Life Insurance JV
HSBC receives regulatory approval from the China Banking and Insurance Regulatory Commission to acquire the remaining 50% equity interest in HSBC Life China.
HSBC gets approval to buy out China life insurance joint venture
HSBC said on Thursday it had received regulatory approval in China to take full ownership of its life insurance joint venture in the country, as it continues to expand its non-core banking services.
Source: https://incomestatements.info
Category: Stock Reports